IGF1 genotype, mean plasma level and breast cancer risk in the Hawaii/Los Angeles multiethnic cohort.
IGF1 genotype, mean plasma level and breast cancer risk in the Hawaii/Los Angeles multiethnic cohort.
复制标题
DOI：
10.1038/sj.bjc.6600728
复制
发表时间：
2003-01-27
影响因子：
8.8
通讯作者：
中科院分区：
文献类型：
--
作者：
胰岛素样生长因子1基因(IGF1)是乳腺癌易感模型的有力候选基因。我们研究了IGF1基因转录起始点上游的二核苷酸重复序列969 碱基与绝经后多民族妇女血浆IGF1水平和乳腺癌风险的可能关联。此外，我们在夏威夷/洛杉矶多民族队列中调查了种族/民族、平均血浆IGF1水平和乳腺癌发病率之间的关系。拉美裔女性经年龄调整后的平均IGF1水平为116 ng m1−1，显著低于其他三个种族/族裔组别的平均年龄调整IGF1水平(分别为146、144和145 ng ml−1)(P<；0.0001)。拉美裔美国女性的乳腺癌发病率是队列中所有种族/民族中最低的。这些结果支持将IGF1在乳腺癌发生中的重要作用的假设扩展到不同种族/民族和绝经后妇女的研究。IGF1在乳腺癌病因学中的任何参与都不太可能是由IGF1二核苷酸重复多态介导的，在本研究中，IGF1二核苷酸重复多态与循环中的IGF1水平或乳腺癌风险没有显著相关性。必须继续研究血液中IGF1水平的相关决定因素。
The insulin-like growth factor 1 gene (IGF1) is a strong candidate gene for a breast cancer susceptibility model. We investigated a dinucleotide repeat 969 bp upstream from the transcription start site of the IGF1 gene for possible associations with plasma IGF1 levels and breast cancer risk in a multiethnic group of postmenopausal women. Furthermore, we investigated the relation between race/ethnicity, mean plasma IGF1 levels and breast cancer rates in the Hawaii/Los Angeles Multiethnic Cohort. The mean age-adjusted IGF1 level among Latino-American women, 116 ng ml−1, was statistically significantly lower than the mean age-adjusted IGF1 levels for each of the three other racial/ethnic groups, African-American, Japanese-American and Non-Latino White women (146, 144 and 145 ng ml−1, respectively) (P<0.0001). Latino-American women have the lowest breast cancer rates of any racial/ethnic group in the cohort. These results support the investigation of an expansion of the hypothesis for an important role of IGF1 in breast cancer tumorigenesis to different racial/ethnic groups and to postmenopausal women. It is unlikely that any involvement of IGF1 in breast cancer aetiology is mediated by the IGF1 dinucleotide repeat polymorphism, which was not significantly associated with circulating IGF1 levels nor breast cancer risk in this study. Research into relevant determinants of IGF1 levels in the blood must continue.